Topics
May/June 2023 | Subfocus
Quantifying Fluid in AMD
Central subfoveal thickness isn’t the only biomarker clinicians can use to track disease progression and treatment effect.
Stela Vujosevic, MD, PhD, FARVO, FEBO
Clinical Trial Designs in Wet AMD: A Brief Review
Can newer therapies improve upon visual acuity and other outcomes for patients?
Carl D. Regillo, MD
The Effect of Biosimilars on Clinical Practice
A look at the true cost of the new drugs that are shaking up our therapeutic approaches.
Margaret M. Runner, MD, and George A. Williams, MD
November 17, 2026
MacuMira Receives CE Mark Certification for Retinal Microcurrent Stimulation Device to Treat Dry AMD
November 16, 2026
Johnson & Johnson to Acquire Ollin Biosciences for $2.2 Billion, Advancing Retinal Disease Pipeline
RetinaLyze System Receives EU MDR Class 2a Certification for Retinal Screening Software
November 11, 2026
AAO, AOA Respond to FDA GLP-1 Drug Labeling Changes, Highlight NAION Risk and Eye Care Recommendations
October 2026 Insert
Editorially Independent Content, Supported With Advertising From Asetllas
Editorially independent supported by Abbvie and Regenxbio
Supported by Zeiss
Free Print Subscription
Email Newsletter
Conference Calendar